Aubrai debuts on Bio Protocol’s launchpad with a vision to democratize scientific funding and governance.
The persistent challenge facing longevity and regenerative medicine is often not scientific know-how, but rather how innovative projects secure funds to cross the infamous “valley of death” between lab breakthroughs and real-world application. Enter Aubrai, a decentralized science (DeSci) platform that has launched as part of the Bio Protocol on Coinbase’s Layer-2 blockchain, Base. Blending blockchain, artificial intelligence and collective action, Aubrai aims to support a new era of biomedicine research and development.
Longevity.Technology: What sets Aubrai apart is its foundation in thousands of private lab notes, internal chats and unpublished insights from the lab of Dr. Aubrey de Grey and the collective intelligence of the global longevity community. Rather than relying solely on traditional philanthropic or venture capital models, the platform enables token holders to shape research agendas, vote on funding allocations, and potentially share in the rewards of successful discoveries.
The Aubrai project manifesto on bio.xyz, states, “Co-developed by VitaDAO and BIO, the first BioAgent is designed to fight the greatest killer of all time: Aging. As an onchain AI co-scientitst, Aubrai can generate and validate hypotheses, design wet-lab experiments and encrypt data when asked, enriching research outputs while protecting trade secrets.”
“The consequences of traditional financing are a chronic funding gap, over-reliance on philanthropy, and a ‘valley of death’ between discovery and the clinic,” de Grey told CoinDesk in an interview. “That’s why we champion alternative mechanisms – DAOs, longevity-focused venture funds, and DeSci platforms – which can tolerate long horizons, align incentives around societal benefit, and crowd-source risk.”
At the heart of Aubrai’s mission lies the Robust Mouse Rejuvenation (RMR2) project – de Grey’s ambitious study to double the remaining lifespan of middle‑aged mice. The protocols agent ingests experiments into a knowledge graph, generates hypotheses, and routes them to token-holder votes for funding. Once experiments are validated, discoveries are minted into IP-tokens that can be licensed to pharmaceutical or biotech firms, with revenues cycling back to researchers and contributors.
“We are already seeing the agent formulate intriguing new hypotheses and recommend next steps,” de Grey told CoinDesk. “It’s the combination of agentic AI intelligence and expert human intelligence that has the potential to dramatically speed up breakthroughs in the fight against aging.”
“Having the agent at our disposal has been transformative for our planning pipeline,” de Grey added, noting that RMR2 involves nearly a dozen overlapping studies. “It identified points of consideration we had not yet encountered through literature, and it was proactive in suggesting ways to circumvent foreseen limitations.”
For Bio Protocol’s founder Paul Kohlhaas, Aubrai represents a turning point in how science can be organized and financed.
“Just as Substack gave writers the ability to monetize outside legacy media, Bio’s infrastructure can turn scientists into the next great creator economy,” he said on CoinDesk.
DeSci will face challenges
While projects like Aubrai and Bio Protocol demonstrate the potential of crypto capital beyond memecoins, tokenized intellectual property is still in the foothills compared to traditional IP and ringfencing with established pharmaceutical firms still to prove adoption of discoveries born out of decentralized collectives.
However, for a field like longevity, where breakthroughs often die in the space between early results and human trials due to a lack of capital, Aubrai offers an alternative path. If it succeeds, it could demonstrate blockchain’s potential to do more than just pump the next memecoin; providing the infrastructure to accelerate research itself, pushing the field of longevity closer to therapies that extend human healthspan.
Currently, the ‘Ignition Sale’ of Aubrai is 7.4X oversubscribed.
